Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NN-9931?

NN-9931 is a recombinant peptide commercialized by Novo Nordisk, with a leading Phase III program in Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Insilico Medicine’s AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances.

April 13, 2024

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 23, 2024

SYNLAB affected by cyber-attack in Italy – Biotech Investments

SYNLAB AG / Key word(s): Statement SYNLAB AG: SYNLAB affected by cyber-attack in Italy 19-Apr-2024 / 19:06 CET/CEST Disclosure of an inside information acc. to

April 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.